Video yükleniyor...
Video Yüklenemedi
This is a truly historic moment. The results from this pivotal trial evaluating a fully percutaneous transcatheter mitral valve replacement technology has opened a new treatment option for patients who are not good candidates for surgery or TEER. This is a remarkable milestone that will not only transform the... show more
20,964 görüntüleme • 11 ay önce •via X (Twitter)
11 Yorum

Awesome study Mayra et al! Also 50% women! 👏🏽👏🏽👏🏽👏🏽

Congrats, dear Doctor. Just one question: As far as I can anticipate, it is more likely to develop high transmitral gradient than residual regurgitation (in addition to LVOTO). What was the mean gradient after the procedure in this study before hospital discharge (not in the OR)?

The mean MVG at discharge (5.2 mmHg) was essentially the same at 30 days (5.4 mmHg). Thank you

Gracias, Dra. Mayra. Sí me interesa el TMVR. Creo que tiene mucho potencial, cosa que nunca vi en TEER, por las razones limitantes que usted ya sabe. Felicitaciones por su gran esfuerzo!

Congratulations! This is truly an amazing breakthrough!

Nice summary - agree and thanks for sharing

Congratulations!!!

Congrats 🎉 @MayraGuerreroMD

What a great achievement. Congratulations.

This breakthrough in mitral valve replacement technology is a game changer for cardiology offering new hope to patients who were previously out of options truly a monumental achievement

@DrMarthaGulati Reassuring but wish there was a control group. Don't think we can truly say there is benefit without it.
